Synthesis and Characterization of Thrombin Conjugated γ‐Fe2O3 Magnetic Nanoparticles for Hemostasis
Source abstract
Abstract
Abstract Thrombin is the final protease produced in the clotting pathways. Thrombin has been used in the clinic more than six decades for topical hemostasis and wound management. In human plasma the half‐life of thrombin is shorter than 15 seconds due to close control by inhibitors. In order to stabilize thrombin, this enzyme was conjugated covalently and physically to γ‐Fe2O3 magnetic nanoparticles. The physical conjugation was accomplished through adsorption of thrombin to BSA coating on the nanoparticles. The coagulant activity of the covalently bound thrombin was significantly lower than that of the physically adsorbed thrombin. Leakage of the physically bound thrombin into PBS containing 4% HSA was negligible. The physical conjugation of thrombin onto the nanoparticles stabilized the thrombin against its major inhibitor antithrombin III and improved its storage stability. At optimal CaCl2 concentration, the clotting time by the bound thrombin is shorter than that of the free enzyme. This novel conjugated thrombin may be an efficient candidate for topical hemostasis and wound healing.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Polymer Surface Interaction Studies · Nanoparticle-Based Drug Delivery · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. Putnam F. W. · 1975
2. 10.1160/TH03-12-079210.1160/TH03-12-0792 ↗
3. 10.1161/01.RES.77.4.64510.1161/01.RES.77.4.645 ↗
4. 10.1172/JCI11573710.1172/JCI115737 ↗
5. 10.1016/S0002-9610(01)00774-710.1016/S0002-9610(01)00774-7 ↗
6. 10.1007/BF0157110910.1007/BF01571109 ↗
7. 10.1016/0142-9612(95)93113-R10.1016/0142-9612(95)93113-R ↗
8. 10.1016/j.beha.2005.01.00910.1016/j.beha.2005.01.009 ↗
9. 10.1055/s-0028-108528810.1055/s-0028-1085288 ↗
10. Canonico S. · Acta. Bio. Medica. · 2003 · 74 · 21
11. 10.1016/S0002-9440(10)63935-110.1016/S0002-9440(10)63935-1 ↗
12. Jesty J. · J. Biol. Chem. · 1986 · 261 · 1031310.1016/S0021-9258(18)67526-X ↗
13. 10.1016/j.expneurol.2005.01.02010.1016/j.expneurol.2005.01.020 ↗
14. 10.1016/S0169-409X(02)00044-310.1016/S0169-409X(02)00044-3 ↗
15. S.Margel L.Sheichat T.Tennenbaum US 20060104970 (2006) Bar‐Ilan University Israel: Abstr. WO 2004045494 (A2).
16. J. S.Dordick R. S.Kane P.Asuri S.Karajanagi US 20090143487 (2009) WO 2007001355 (2007) Rensselaer Polytachnic Institute USA) Abstr. WO 2007001355 (A2).
17. S.Margel S.Gura EP 1088315 (2003) IL 139638 (2006) Bar‐Ilan University Israel: Abstr. WO 9962079 (A1).
18. 10.1002/jbm.a.3151810.1002/jbm.a.31518 ↗
19. Margel S. · 2008
20. Okon E. · Lab. Invest. · 1994 · 71 · 895
21. 10.1097/01.rli.0000129472.45832.b010.1097/01.rli.0000129472.45832.b0 ↗
22. 10.1038/nbt115410.1038/nbt1154 ↗
23. 10.1016/0003-2697(76)90527-310.1016/0003-2697(76)90527-3 ↗
24. 10.1215/15228517-2008-00210.1215/15228517-2008-002 ↗
25. 10.1002/(SICI)1099-0518(20000201)38:3<653::AID-POLA29>3.0.CO;2-P10.1002/(SICI)1099-0518(20000201)38:3<653::AID-POLA29>3.0.CO;2-P ↗
26. Streitwieser A. · 1992
27. Rappoport Z. · 1964
28. Peters T. J. · 1996
29. Berg W. · I. Lundstrom, Thromb. Haemos. · 1979 · 42 · 97210.1055/s-0038-1656988 ↗
30. 10.1021/bm061197b10.1021/bm061197b ↗
31. 10.1111/j.1749-6632.2001.tb03516.x10.1111/j.1749-6632.2001.tb03516.x ↗
32. 10.1042/bj239051310.1042/bj2390513 ↗
33. McLean F. C. · J. Biol. Chem. · 1935 · 108 · 28510.1016/S0021-9258(18)75332-5 ↗
34. Aguanno J. J. · J. Biol. Chem. · 1982 · 257 · 874510.1016/S0021-9258(18)34191-7 ↗